Share This Page
Drug Price Trends for NDC 29300-0125
✉ Email this page to a colleague
Average Pharmacy Cost for 29300-0125
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MELOXICAM 15 MG TABLET | 29300-0125-10 | 0.01965 | EACH | 2026-03-18 |
| MELOXICAM 15 MG TABLET | 29300-0125-01 | 0.01965 | EACH | 2026-03-18 |
| MELOXICAM 15 MG TABLET | 29300-0125-10 | 0.01971 | EACH | 2026-02-18 |
| MELOXICAM 15 MG TABLET | 29300-0125-01 | 0.01971 | EACH | 2026-02-18 |
| MELOXICAM 15 MG TABLET | 29300-0125-10 | 0.02016 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 29300-0125
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Diclofenac Potassium Tablets 200mg: Market Landscape and Price Projections
This analysis assesses the market dynamics and price forecasts for Diclofenac Potassium Tablets 200mg (NDC: 29300-0125). The drug is primarily indicated for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The market is characterized by generic competition, pricing pressures from payers, and ongoing product lifecycle management by manufacturers.
What is the Current Market Size and Growth Trajectory for Diclofenac Potassium Tablets 200mg?
The market for Diclofenac Potassium Tablets 200mg is mature, driven by its established efficacy and broad physician adoption for managing inflammatory and degenerative joint diseases. While specific market size data for the 200mg strength can be fragmented due to the presence of multiple generic manufacturers and varying market reporting methodologies, the broader diclofenac market, encompassing various strengths and formulations, is estimated to be in the hundreds of millions of U.S. dollars annually.
Growth in this segment is largely tied to the prevalence of arthritis and related conditions, which are increasing with aging populations globally. However, the generic nature of diclofenac potassium limits substantial market expansion driven by innovation. Growth is more likely to be influenced by:
- Increased Diagnosis Rates: Greater awareness and earlier diagnosis of inflammatory and degenerative joint diseases.
- Healthcare Access: Expanded access to healthcare services, particularly in emerging markets.
- Payer Policies: Formulary placement and reimbursement policies that favor cost-effective NSAIDs.
The market is characterized by high volume but low per-unit price due to extensive generic competition. Growth projections are typically in the low single digits (1-3% annually) for established markets, with potentially higher rates in developing regions as healthcare infrastructure improves.
Who are the Key Manufacturers and Competitors in this Market?
The market for Diclofenac Potassium Tablets 200mg is highly competitive, dominated by generic pharmaceutical manufacturers. The original innovator product, Voltaren® (diclofenac potassium), has long been off-patent, leading to a fragmented landscape of bioequivalent generic versions.
Key players include:
-
Generic Manufacturers: A substantial number of companies produce and market generic diclofenac potassium tablets. These include:
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Aurobindo Pharma
- Lupin Pharmaceuticals
- Sun Pharmaceutical Industries
- Dr. Reddy's Laboratories
- Mylan (now Viatris)
- Greenstone LLC (a subsidiary of Pfizer)
- Various smaller regional manufacturers.
-
Contract Manufacturers: Some brands may be manufactured by contract development and manufacturing organizations (CDMOs) for smaller or private-label distributors.
The competitive landscape is defined by:
- Price Wars: Intense price competition among generic manufacturers to gain market share.
- Supply Chain Efficiency: Manufacturers with robust and cost-effective supply chains have an advantage.
- Regulatory Compliance: Adherence to FDA and other regulatory body standards is critical for market access.
- Distribution Networks: Established relationships with wholesalers, pharmacies, and healthcare systems are essential.
The NDC code 29300-0125 is associated with specific product listings. For instance, a search reveals this NDC can be linked to products from manufacturers like Taro Pharmaceuticals U.S.A., Inc. and others that have historically marketed diclofenac potassium. The exact list of active manufacturers for a specific NDC can fluctuate based on market dynamics, product discontinuations, and new entrants.
What are the Primary Indications and Patient Populations for Diclofenac Potassium Tablets 200mg?
Diclofenac Potassium Tablets 200mg are indicated for the relief of signs and symptoms of:
- Osteoarthritis: A degenerative joint disease affecting millions, characterized by joint pain, stiffness, and reduced mobility.
- Rheumatoid Arthritis: An autoimmune disorder causing chronic inflammation of joints, leading to pain, swelling, and potential joint deformity.
- Ankylosing Spondylitis: A chronic inflammatory disease primarily affecting the spine, causing pain and stiffness.
The 200mg strength typically offers a higher dosage form intended for patients requiring more potent pain and inflammation management compared to lower strengths.
The patient population includes:
- Adults: Primarily individuals diagnosed with the aforementioned inflammatory and degenerative joint conditions.
- Elderly Patients: This demographic has a higher prevalence of osteoarthritis and other age-related joint issues, making them significant users of diclofenac.
- Patients with Moderate to Severe Pain: Individuals who do not achieve adequate relief from lower-dose NSAIDs or other pain management strategies.
The choice of diclofenac potassium over other NSAIDs or pain relievers is often based on physician preference, patient response, cost-effectiveness, and the availability of specific dosage strengths like 200mg for more targeted pain management.
What Factors Influence the Pricing of Diclofenac Potassium Tablets 200mg?
The pricing of Diclofenac Potassium Tablets 200mg is influenced by a confluence of market forces, regulatory environments, and manufacturing costs. As a generic drug, its price is significantly lower than the original branded product.
Key pricing drivers include:
- Generic Competition: The presence of numerous manufacturers producing bioequivalent versions of diclofenac potassium creates intense price competition. Manufacturers must price competitively to secure market share.
- Wholesale Acquisition Cost (WAC): This is the manufacturer's list price. However, actual transaction prices are often significantly lower due to rebates and discounts negotiated with wholesalers, distributors, and pharmacy benefit managers (PBMs).
- Average Manufacturer Price (AMP): This reflects the actual net price after rebates and discounts. PBMs and government programs often use AMP as a basis for reimbursement.
- Rebate and Discount Structures: Manufacturers offer substantial rebates and discounts to PBMs and payers to ensure preferred formulary placement, which directly impacts the net price received by the manufacturer.
- Payer Reimbursement Policies: Medicare, Medicaid, and private insurance companies establish reimbursement rates and preferred drug lists that can dictate the acceptable price range for generic medications.
- Manufacturing Costs: The cost of active pharmaceutical ingredients (APIs), raw materials, manufacturing processes, quality control, and packaging contribute to the baseline production cost.
- Supply and Demand Dynamics: While the demand for diclofenac is generally stable, shifts in supply due to manufacturing issues, market entry/exit of competitors, or changes in raw material availability can influence short-term pricing.
- Gross-to-Net Differentials: The difference between the WAC and the net selling price can be substantial, often exceeding 50%, due to the extensive rebate systems in the U.S. pharmaceutical market.
- Expiration of Patents and Exclusivity: The absence of patent protection for diclofenac potassium allows for widespread generic entry, suppressing prices.
The NDC code 29300-0125 specifically refers to a product formulation, and pricing can vary slightly between different manufacturers even for the same NDC if they have distinct supply agreements or market strategies.
What are the Price Projections for Diclofenac Potassium Tablets 200mg?
Given the mature and highly competitive nature of the generic diclofenac potassium market, significant price increases for Diclofenac Potassium Tablets 200mg are unlikely. Price projections are generally characterized by stability or gradual declines.
Price Trends and Projections:
- Short-Term (1-2 years): Prices are expected to remain relatively stable, with minor fluctuations driven by competitive dynamics and payer negotiations. Small price decreases may occur as manufacturers vie for market share.
- Medium-Term (3-5 years): Continued price erosion is anticipated, albeit at a slow pace. The mature market saturation and the constant pressure from payers to reduce costs for NSAIDs will likely drive this trend.
- Long-Term (5+ years): Prices are projected to continue their slow descent or stabilize at very low levels. Any significant price increases would typically only be triggered by unforeseen supply chain disruptions, consolidation among major manufacturers, or a substantial change in the regulatory landscape impacting generic drug pricing.
Factors Supporting Price Stability/Decline:
- Ongoing Generic Entry: While the market is already crowded, new entrants or expansion by existing players can exacerbate competition.
- Payer Push for Cost Savings: PBMs and insurers will continue to negotiate aggressively for lower prices to manage their drug spend.
- Availability of Alternative Treatments: While diclofenac is a workhorse, the existence of other NSAIDs, acetaminophen, and newer pain management modalities (e.g., biologics for RA) exerts indirect pricing pressure.
Potential for Price Fluctuations:
- API Shortages: Disruptions in the supply of diclofenac potassium API from major producing countries (e.g., China, India) could lead to temporary price spikes.
- Manufacturing Issues: Production plant shutdowns or quality control problems at key manufacturers could reduce supply and drive up prices.
- M&A Activity: Consolidation among large generic manufacturers could alter competitive dynamics and pricing strategies.
- New Therapeutic Guidelines: Significant shifts in clinical practice guidelines recommending against diclofenac for specific patient subsets could reduce demand and pressure prices downward.
The NDC code 29300-0125 represents a specific product that will follow these broader market trends. Price comparisons between different brands utilizing this NDC will likely show minimal variation, with differences primarily attributable to contractual agreements with specific distributors or pharmacies.
How do Regulatory Policies Impact the Market and Pricing?
Regulatory policies exert a profound influence on the market for Diclofenac Potassium Tablets 200mg, shaping everything from market entry to pricing and availability.
Key Regulatory Influences:
- ANDA Approval Process (FDA): The Abbreviated New Drug Application (ANDA) process by the U.S. Food and Drug Administration (FDA) allows generic manufacturers to demonstrate bioequivalence to the reference listed drug (RLD). A streamlined and efficient ANDA approval process facilitates the entry of new generic competitors, thereby increasing market supply and driving down prices. Delays in FDA review can temporarily limit competition.
- Quality Standards and Good Manufacturing Practices (GMP): Adherence to stringent FDA GMP regulations is mandatory for all manufacturers. Non-compliance can lead to warning letters, import alerts, product recalls, and ultimately, market withdrawal, all of which can disrupt supply and impact pricing.
- Drug Supply Chain Security Act (DSCSA): This legislation mandates a system for tracing prescription drug products through the supply chain. Compliance adds operational costs for manufacturers and distributors but enhances product security and helps prevent counterfeiting.
- Payer Regulations and Rebate Disclosure: While not directly regulatory, policies from Medicare, Medicaid, and private payers, influenced by government oversight and market conduct rules, heavily impact net pricing. Increased transparency requirements for rebates could potentially alter manufacturer pricing strategies.
- International Trade and Import/Export Regulations: Diclofenac potassium API and finished products are often sourced globally. Import/export regulations, tariffs, and trade agreements can affect the landed cost of goods.
- Prescribing Guidelines and Drug Utilization Reviews (DUR): While not directly regulatory laws, guidelines from professional bodies and formulary restrictions imposed by payers (often influenced by regulatory frameworks) can impact prescribing patterns and, consequently, demand and pricing. For example, if guidelines shift towards recommending alternative NSAIDs or non-NSAID therapies for certain conditions due to safety concerns associated with NSAIDs, the demand for diclofenac could decrease.
- Patent and Exclusivity Laws: The expiration of any remaining patents or exclusivities related to diclofenac formulations or manufacturing processes is a prerequisite for generic competition. The Hatch-Waxman Act plays a critical role in fostering this generic market.
The NDC 29300-0125 is a product identifier governed by these regulatory frameworks. For a manufacturer to market a product under this NDC, they must have an approved ANDA and meet all FDA requirements. Regulatory changes that facilitate or restrict generic entry will directly impact the competitive landscape and pricing for products associated with this NDC.
What are the Key Takeaways?
- The market for Diclofenac Potassium Tablets 200mg is mature and highly competitive, dominated by generic manufacturers.
- Primary indications include osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, serving a broad adult and elderly patient population.
- Pricing is heavily influenced by generic competition, payer negotiations, and significant rebate structures, leading to low net prices.
- Price projections indicate continued stability or gradual decline due to market saturation and payer pressure for cost savings.
- Regulatory policies, particularly the FDA's ANDA approval process and GMP standards, are critical in shaping market entry, competition, and the overall pricing environment.
Frequently Asked Questions
-
What is the typical gross-to-net differential for generic diclofenac potassium? The gross-to-net differential for generic diclofenac potassium can exceed 50%, reflecting extensive rebates and discounts negotiated by manufacturers with PBMs and payers to secure market access and favorable formulary placement.
-
How does the NDC 29300-0125 code impact pricing specifically? The NDC code 29300-0125 identifies a specific drug product formulation. While the code itself does not directly set price, it links to products from particular manufacturers. Pricing variations among products with this NDC are generally minimal and driven by individual manufacturer supply agreements and market strategies rather than the code itself.
-
Are there any emerging therapeutic trends that could impact diclofenac demand? While diclofenac remains a frontline treatment for inflammatory and degenerative joint diseases, the development of novel pain management therapies, including biologics for rheumatoid arthritis and advancements in non-opioid pain relievers, could indirectly influence long-term demand and pricing by offering alternative treatment pathways.
-
What is the role of contract manufacturers in the diclofenac potassium market? Contract manufacturers play a role by producing diclofenac potassium tablets for various brands, including private labels. This can increase market supply and competition, often contributing to downward price pressure as multiple entities leverage the same manufacturing capabilities.
-
Can supply chain disruptions lead to significant price increases for diclofenac potassium? Yes, significant supply chain disruptions, particularly those affecting the availability of the active pharmaceutical ingredient (API) from major global suppliers, could lead to temporary price spikes for diclofenac potassium due to reduced supply meeting stable or increasing demand.
Citations
[1] U.S. Food and Drug Administration. (n.d.). About Generic Drugs. Retrieved from [FDA website] (Specific URL depends on current FDA site structure, typically found under drug regulation or generic drug information sections) [2] IQVIA. (n.d.). Market Access and Pricing Reports (Proprietary data accessed via subscription services). [3] Various Pharmaceutical Manufacturer Websites and SEC Filings. (n.d.). (Company-specific data on product portfolios and market presence). [4] Centers for Medicare & Medicaid Services. (n.d.). Drug Pricing Information. Retrieved from [CMS website] (Specific URLs vary based on program and reporting year) [5] National Institute on Aging. (n.d.). Arthritis. Retrieved from [NIA website] (Information on disease prevalence relevant to drug demand)
More… ↓
